A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2, DOSE-FINDING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SAR445399 IN PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Registry ID

EFC18055

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

SANOFI-AVENTIS CANADA INC

Start date

2026-06-17

Last update

2025-12-11

Conditions

• HIDRADENITIS SUPPURATIVA

Related clinical trials

• A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NAV-240 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL TO ASSESS EFFICACY AND SAFETY OF ZASOCITINIB IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2, DOSE-FINDING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SAR445399 IN PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
• A PHASE 2, DOSE RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BFB759 IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (COMPASS 2 - HS)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSERANGING PHASE 2 STUDY OF BRIVEKIMIG FOLLOWED BY A MAINTENANCE PERIOD IN PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA
• A PHASE 2A DOUBLE BLIND, RANDOMIZED, PARALLEL ARM, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFECTS OF TWO DOSE LEVELS OF CIT-013 ON DISEASE ACTIVITY IN PATIENTS WITH HIDRADENITIS SUPPURATIVA (HS)

View on source registry